Menu Search
Equities

Epsilon Healthcare Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9TH0:STU

Epsilon Healthcare Ltd

Actions
  • Price (EUR)0.012
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Epsilon Healthcare Limited is an Australia-based global healthcare and pharmaceuticals company. The Company has a diversified and vertically integrated portfolio of assets, including healthcare, pharmaceutical contract development and manufacturing and pharmacy services. The Company’s segments include Telehealth Medical Practice and Contract Development and Manufacturing. The Company owns medicinal cannabis assets, including the GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport Facility) in Southport, Australia, and the Tetra Health clinic group. Its subsidiaries include Epsilon Pharma Pty Ltd, Metra Holdings Pty Ltd, Epsilon Biotech Pty Ltd, among others.

  • Revenue in AUD (TTM)6.13m
  • Net income in AUD-6.12m
  • Incorporated2016
  • Employees--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.